Sign In
Buy ICU
$3.69
+0.410 (+12.50%)
At Close: Aug 10, 2026
1847 Reports 15.0% Increase in Revenue to $14.9 Million for the First Quarter of 2024
08:30am, Thursday, 16'th May 2024
Gross profit increases 13.3% in Q1 2024 vs Q1 2023 NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 1847 Holdings LLC("1847" or the "Company") (NYSE American:EFSH), a holding company specializing in iden
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
09:45am, Sunday, 28'th Apr 2024
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
12:00pm, Saturday, 20'th Apr 2024
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investo
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
04:00pm, Wednesday, 17'th Apr 2024
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing propriet
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
09:30am, Friday, 12'th Apr 2024
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such invest
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
08:30am, Thursday, 11'th Apr 2024
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
06:24pm, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
04:40pm, Thursday, 28'th Mar 2024
NEW YORK , March 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such inves
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
08:30am, Wednesday, 27'th Mar 2024
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercia
Mulago Hospital seeks Shs10 billion for ICUs
02:15am, Friday, 22'nd Mar 2024
Mulago National Referral Hospital is in need of over Shs10 billion to fully functionalise its intensive care units (ICU). This request was tabled by the hospital’s Ag. Executive Director, Dr. Rosema
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company
March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury
07:53am, Thursday, 22'nd Feb 2024
SCD-PED (Pediatric) is the first FDA-approved product in the Company's Quelimmune™ product family
